Is olanzapine a brain-sparing medication?

Archives of General Psychiatry

Volumn 63, Issue 11, 2006, Pages 1292-

  Joober, Ridha ^a   Schmitz, Norbert ^b   Malla, Ashok ^b   Sengupta, Sarojini ^b   Karma, Sherif ^b  

^a MCGILL UNIVERSITY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE;

BODY MASS; BODY WEIGHT; BRAIN ATROPHY; BRAIN SIZE; BRAIN VENTRICLE; DISEASE DURATION; GRAY MATTER; HUMAN; LETTER; NUTRITIONAL STATUS; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

EID: 33750690988     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.63.11.1292     Document Type: Letter

References (5)

1. Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, Keefe RS, Green AI, Gur RE, McEvoy J, Perkins D, Hamer RM, Gu H, Tohen M; HGDH Study Group. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry. 2005;62:361-370.
2. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer RM; HGDH Study Group. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry. 2003;160:1396-1404.
3. Ho KC, Roessmann U, Straumfjord JV, Monroe G. Analysis of brain weight, II: adult brain weight in relation to body height, weight, and surface area. Arch Pathol Lab Med. 1980;104:640-645.
4. Swayze VW, Andersen A, Arndt S, Rajarethinam R, Fleming F, Sato Y, Andreasen NC. Reversibility of brain tissue loss in anorexia nervosa assessed with a computerized Talairach 3-D proportional grid. Psychol Med. 1996;26:381-390.
5. Norman RM, Malla AK. Duration of untreated psychosis: a critical examination of the concept and its importance. Psychol Med. 2001;31:381-400.